leadf
logo-loader
viewNemaura Medical Inc

Nemaura Medical re-launches corporate website and its flagship program BEATdiabetes website

The BEATdiabetes website serves as the unofficial launch of the program and allows users to register and learn about participating to potentially reverse Type 2 diabetes

Nemaura Medical Inc - Nemaura Medical Inc re-launches corporate website and website for its flagship program BEATdiabetes
SugarBEAT is a patented, CE marked, needle-free CGM that is easily applied to the skin via a patch

Nemaura Medical Inc (NASDAQ:NMRD) (FRA:N18A) has re-launched its corporate website www.nemauramedical.com and the website www.beatdiabetes.life for its flagship program BEATdiabetes. 

In a statement Tuesday, the UK-based company said the BEATdiabetes website serves as the unofficial launch of the program and allows users to register and learn about participating in an overall health management system to potentially reverse Type 2 diabetes. 

“The launch of the BEATdiabetes program website is an important entry into the market to allow consumers to access many of the life management tools that come with the program,” said CEO Dr Faz Chowdhury. 

READ: Nemaura Medical licenses Type 2 diabetes weight management mobile app

“In addition to introducing the smartphone and tablet app, which will provide users with our scientifically validated, personalized coaching driven by our digital platform, it also provides users with a portal to become among the first to access our non-invasive glucose monitor, which we expect to launch shortly,” he added. 

Dr Chowdhury said the company believes that the combined use of the app with its sugarBEAT monitor has the potential to help reduce diabetes risk and even potentially reverse Type 2 diabetes with continued and dedicated use.

SugarBEAT is a patented, CE marked, needle-free CGM that is easily applied to the skin via patch. The device transmits blood glucose data to a mobile app to allow for better monitoring or treatment.

“In addition, the re-launch of our corporate website provides visitors with a more comprehensive view of our company,” he said.

“Previously, many visitors had equated one of our single products with the company in general. However, Nemaura is constantly developing its technology and already has designed multiple products that are in the process of being refined for regulatory approval and launch.”

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

 

Quick facts: Nemaura Medical Inc

Price: 4.25 USD

NASDAQ:NMRD
Market: NASDAQ
Market Cap: $97.36 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Nemaura Medical Inc named herein, including the promotion by the Company of Nemaura Medical Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Full interview: Nemaura Medical reveals details of upcoming European launch...

Nemaura Medical Inc (NASDAQ:NMRD) Vice President of Strategy & Strategic Alliances Dr Fred Schaebsdau tells Proactive the medical technology company is targeting a commercial launch for its flagship SugarBEAT continuous glucose monitor in the UK and in Ireland in January 2020. Dr...

on 10/08/2019

2 min read